POU class 2 homeobox 3Genealiases: Epoc-1 · OCT-11 · OCT11 · OTF-11 · PLA-1 · PLA1
Q-omics provides the consensus-scored POU2F3 profile across patient tissues and cancer cell-line models. POU2F3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, POU2F3 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, POU2F3 RNA expression shows 13,315 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, THCA, and TGCT as cancer lineages where POU2F3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POU2F3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POU2F3 survival associations across molecular data types. POU2F3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POU2F3 RNA expression–survival associations across cancer types. High POU2F3 expression shows unfavorable associations in KIRP, UCEC, UVM and PAAD, but favorable associations in THCA and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for POU2F3 RNA expression.
This table summarizes POU2F3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POU2F3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POU2F3 shows lower tumor expression in KIRC and COAD and higher tumor expression in THCA, LIHC, BRCA and CHOL. The THCA box plot shows higher POU2F3 RNA expression in tumor versus normal tissue (log2 FC = +1.401, t-test p < 0.001).
This table shows molecular features associated with POU2F3 in patient tissues and cancer cell lines. In patient samples, POU2F3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, POU2F3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SKIN.
